Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide
Open Access
- 1 October 1996
- journal article
- Published by Elsevier in Current Opinion in Immunology
- Vol. 8 (5) , 710-720
- https://doi.org/10.1016/s0952-7915(96)80090-2
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- REGULATION OF B CELL FUNCTION BY THE IMMUNOSUPPRESSIVE AGENT LEFLUNOMIDE1Transplantation, 1996
- Mechanism of Action of Mycophenolate MofetilTherapeutic Drug Monitoring, 1995
- A Novel FK506 Binding Protein Can Mediate the Immunosuppressive Effects of FK506 and Is Associated with the Cardiac Ryanodine ReceptorJournal of Biological Chemistry, 1995
- FUNCTIONAL AND STRUCTURAL CHARACTERISTICS OF EXPERIMENTAL FK 506 NEPHROTOXICITYClinical and Experimental Pharmacology and Physiology, 1995
- Dihydroorotate Dehydrogenase Is a High Affinity Binding Protein for A77 1726 and Mediator of a Range of Biological Effects of the Immunomodulatory CompoundJournal of Biological Chemistry, 1995
- The Rapamycin and FKBP12 Target (RAFT) Displays Phosphatidylinositol 4-Kinase ActivityPublished by Elsevier ,1995
- Leflunomide, a reversible inhibitor of pyrimidine biosynthesis?Inflammation Research, 1995
- Leflunomide interferes with pyrimidine nucleotide biosynthesisInflammation Research, 1995
- Inhibition of Interleukin 2 (IL-2)-stimulated tyrosine kinase activity by leflunomideInflammation Research, 1994
- Rapamycin: FK506's fraternal twin or distant cousin?Immunology Today, 1991